FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Frédéric Triebel

Research Profile

Anatomy

Chemicals & Drugs

Concepts & Ideas

Physiology

Disorders

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Chiara Camisaschi; Chiara Casati; Francesca Rini; Michela Perego; Annamaria De Filippo; Frédéric Triebel; Giorgio Parmiani; Filiberto Belli; Licia Rivoltini; Chiara Castelli
LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.
Chiara Casati; Chiara Camisaschi; Luisa Novellino; Arabella Mazzocchi; Frédéric Triebel; Licia Rivoltini; Giorgio Parmiani; Chiara Castelli
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Chrystelle Brignone; Caroline Grygar; Manon Marcu; Knut Schäkel; Frédéric Triebel
A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Frédéric Triebel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Chiara Camisaschi; Chiara Casati; Francesca Rini; Michela Perego; Annamaria De Filippo; Frédéric Triebel; Giorgio Parmiani; Filiberto Belli; Licia Rivoltini; Chiara Castelli
LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(11):6545-51.
2008: Chiara Casati; Chiara Camisaschi; Luisa Novellino; Arabella Mazzocchi; Frédéric Triebel; Licia Rivoltini; Giorgio Parmiani; Chiara Castelli
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(6):3782-8.
2007: Chrystelle Brignone; Caroline Grygar; Manon Marcu; Knut Schäkel; Frédéric Triebel
A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(6):4202-11.
2007: Jagadeesh Bayry; Sophie Sibéril; Frédéric Triebel; David F Tough; Srini V Kaveri
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.
Drug discovery today 2007;12(13-14):548-52.
2007: Chrystelle Brignone; Caroline Grygar; Manon Marcu; Gaëlle Perrin; Frédéric Triebel
IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study.
Vaccine 2007;25(24):4641-50.
2007: Simone A Joosten; Krista E van Meijgaarden; Nigel D L Savage; Tjitske de Boer; Frédéric Triebel; Annemieke van der Wal; Emile de Heer; Michel Klein; Annemieke Geluk; Tom H M Ottenhoff
Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(19):8029-34.
2007: Jagadeesh Bayry; Frédéric Triebel; Srini V Kaveri; David F Tough
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(7):4184-93.
2007: Chrystelle Brignone; Caroline Grygar; Manon Marcu; Gaëlle Perrin; Frédéric Triebel
IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study.
Journal of immune based therapies and vaccines 2007;5():5.
2006: Sylvie Fougeray; Chrystelle Brignone; Frédéric Triebel
A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321.
Vaccine 2006;24(26):5426-33.
2006: Chiara Casati; Chiara Camisaschi; Francesca Rini; Flavio Arienti; Licia Rivoltini; Frédéric Triebel; Giorgio Parmiani; Chiara Castelli
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
Cancer research 2006;66(8):4450-60.
2006: Frédéric Triebel; Kamel Hacene; Marie-France Pichon
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
Cancer letters 2006;235(1):147-53.
2005: Laëtitia Maçon-Lemaître; Frédéric Triebel
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
Immunology 2005;115(2):170-8.
2005: Sandrine Buisson; Frédéric Triebel
LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.
Immunology 2005;114(3):369-74.
2003: Frédéric Triebel
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.
Trends in immunology 2003;24(12):619-22.
2003: Susanne Andreae; Sandrine Buisson; Frédéric Triebel
MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).
Blood 2003;102(6):2130-7.
2003: Sandrine Buisson; Frédéric Triebel
MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells.
Vaccine 2003;21(9-10):862-8.
2002: Susanne Andreae; Fabienne Piras; Nicolas Burdin; Frédéric Triebel
Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).
Journal of immunology (Baltimore, Md. : 1950) 2002;168(8):3874-80.
2001: N Iouzalen; Susanne Andreae; S Hannier; Frédéric Triebel
LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway.
European journal of immunology 2001;31(10):2885-91.
2001: Christian E Demeure; J Wolfers; N Martin-Garcia; P Gaulard; Frédéric Triebel
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1709-18.
2001: B Huard; Lars Karlsson; Frédéric Triebel
KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation.
European journal of immunology 2001;31(6):1728-35.
2001: S El Mir; A Casanova; D Betbeder; Frédéric Triebel
A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration.
European journal of cancer (Oxford, England : 1990) 2001;37(8):1053-60.
2000: S El Mir; Frédéric Triebel
A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(11):5583-9.
2000: Miriam Merad; Eric Angevin; J Wolfers; Caroline Flament; I Lorenzi; Frédéric Triebel; Bernard Escudier; Laurence Zitvogel
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(3):369-78.
1999: P Prigent; S El Mir; M Dréano; Frédéric Triebel
Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses.
European journal of immunology 1999;29(12):3867-76.
1999: S Hannier; Frédéric Triebel
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
International immunology 1999;11(11):1745-52.
1999: Eric Angevin; L Glukhova; C Pavon; A Chassevent; Marie-José Terrier-Lacombe; AF Goguel; J Bougaran; Patrice Ardouin; Bernard Court; JL Perrin; G Vallancien; Frédéric Triebel; Bernard Escudier
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis.
Laboratory investigation; a journal of technical methods and pathology 1999;79(7):879-88.
1999: C Ronsin; V Chung-Scott; Isabelle Poullion; N Aknouche; Catherine Gaudin; Frédéric Triebel
A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):483-90.
1999: MN Avice; Marika Sarfati; Frédéric Triebel; Guy Delespesse; Christian E Demeure
Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(5):2748-53.
1999: Catherine Gaudin; F Kremer; Eric Angevin; V Scott; Frédéric Triebel
A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1730-8.
1998: S Hannier; Muriel Tournier; Georges Bismuth; Frédéric Triebel
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(8):4058-65.
1998: N Alatrakchi; Françoise Farace; E Frau; Patrice Carde; Jean-Nicolas Munck; Frédéric Triebel
T-cell clonal expansion in patients with B-cell lymphoproliferative disorders.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):363-70.
1998: D Bruniquel; N Borie; S Hannier; Frédéric Triebel
Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II.
Immunogenetics 1998;48(2):116-24.
1998: B Huard; Muriel Tournier; Frédéric Triebel
LAG-3 does not define a specific mode of natural killing in human.
Immunology letters 1998;61(2-3):109-12.
1997: Eric Angevin; F Kremer; Catherine Gaudin; T Hercend; Frédéric Triebel
Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity.
International journal of cancer. Journal international du cancer 1997;72(3):431-40.
1997: Françoise Farace; Eric Angevin; Isabelle Poullion; C Leboullaire; G Ferir; D Elias; Bernard Escudier; Frédéric Triebel
T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines.
International journal of cancer. Journal international du cancer 1997;71(6):972-7.
1997: B Huard; Renato Mastrangeli; P Prigent; D Bruniquel; Silvia Donini; N El-Tayar; Bernard Maigret; M Dréano; Frédéric Triebel
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(11):5744-9.
1997: D Bruniquel; N Borie; Frédéric Triebel
Genomic organization of the human LAG-3/CD4 locus.
Immunogenetics 1997;47(1):96-8.
1996: Anne Caignard; M Guillard; Catherine Gaudin; Bernard Escudier; Frédéric Triebel; Pierre-Yves Dietrich
In situ demonstration of renal-cell-carcinoma-specific T-cell clones.
International journal of cancer. Journal international du cancer 1996;66(4):564-70.
1996: B Huard; P Prigent; F Pagès; D Bruniquel; Frédéric Triebel
T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding.
European journal of immunology 1996;26(5):1180-6.
1996: A Kumar; Françoise Farace; C Gaudin; Frédéric Triebel
Clonal T cell expansion induced by interleukin 2 therapy in blood and tumors.
The Journal of clinical investigation 1996;97(5):1219-26.
1996: D Valteau; V Scott; G Carcelain; Olivier Hartmann; Bernard Escudier; T Hercend; Frédéric Triebel
T-cell receptor repertoire in neuroblastoma patients.
Cancer research 1996;56(2):362-9.
1995: Eric Angevin; Dominique Valteau-Couanet; Françoise Farace; Pierre-Yves Dietrich; A Lecesne; Frédéric Triebel; Bernard Escudier
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):188-95.
1995: Dominique Elias; Françoise Farace; Frédéric Triebel; J M Hattchouel; J P Pignon; A Lecesne; Philippe Rougier; Philippe Lasser; P Duvillard; Bernard Escudier
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Journal of the American College of Surgeons 1995;181(4):303-10.
1995: Françoise Farace; Eric Angevin; Pierre-Yves Dietrich; C Leboullaire; J Vanderplancke; Bernard Escudier; Frédéric Triebel
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo.
International journal of cancer. Journal international du cancer 1995;62(5):523-8.
1995: B Huard; P Prigent; M Tournier; D Bruniquel; Frédéric Triebel
CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins.
European journal of immunology 1995;25(9):2718-21.
1995: Catherine Gaudin; Pierre-Yves Dietrich; S Robache; M Guillard; Bernard Escudier; M J Lacombe; A Kumar; Frédéric Triebel; Anne Caignard
In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
Cancer research 1995;55(3):685-90.
1995: Jos Even; A Lim; Isabelle Puisieux; L Ferradini; Pierre-Yves Dietrich; Antoine Toubert; T Hercend; Frédéric Triebel; C Pannetier; Philippe Kourilsky
T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases.
Research in immunology 1995;146(2):65-80.
1994: Françoise Farace; Eric Angevin; J Vanderplancke; Bernard Escudier; Frédéric Triebel
The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration.
International journal of cancer. Journal international du cancer 1994;59(6):752-5.
1994: B Huard; M Tournier; T Hercend; Frédéric Triebel; Florence Faure
Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes.
European journal of immunology 1994;24(12):3216-21.
1994: Françoise Farace; F Orlanducci; Pierre-Yves Dietrich; Catherine Gaudin; Eric Angevin; M H Courtier; Chantal Bayle; T Hercend; Frédéric Triebel
T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(9):4281-90.
1994: Pierre-Yves Dietrich; Anne Caignard; A Lim; V Chung; José-Luis Pico; C Pannetier; Philippe Kourilsky; T Hercend; Jos Even; Frédéric Triebel
In vivo T-cell clonal amplification at time of acute graft-versus-host disease.
Blood 1994;84(8):2815-20.
1994: Caroline Flament; A Benmerah; M Bonneville; Frédéric Triebel; Fathia Mami-Chouaib
Human TCR-gamma/delta alloreactive response to HLA-DR molecules. Comparison with response of TCR-alpha/beta.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(7):2890-904.
1994: C Genevée; Françoise Farace; V Chung; A Diu; C Raffoux; D Charron; T Hercend; Frédéric Triebel
Influence of human leukocyte antigen genes on TCR V gene segment frequencies.
International immunology 1994;6(10):1497-504.
1994: Françoise Farace; F Kremer; Pierre-Yves Dietrich; C Gaudin; Eric Angevin; M H Courtier; Chantal Bayle; T Hercend; Frédéric Triebel
[Repertory of T lymphocytes in patients with stage A chronic lymphoid leukemia: revealed by monoclonal expansion of T cells in vivo].
Bulletin du cancer 1994;81(10):897-9.
1994: E Savelieva; Françoise Farace; Eric Angevin; D Elias; Bernard Escudier; P Duvillard; T Hercend; Frédéric Triebel
T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(1):66-76.
1994: Françoise Farace; Marc Pallardy; Eric Angevin; T Hercend; Bernard Escudier; Frédéric Triebel
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring.
International journal of cancer. Journal international du cancer 1994;57(6):814-21.
1994: A Mackensen; G Carcelain; S Viel; M C Raynal; H Michalaki; Frédéric Triebel; Jacques Bosq; T Hercend
Direct evidence to support the immunosurveillance concept in a human regressive melanoma.
The Journal of clinical investigation 1994;93(4):1397-402.
1994: Anne Caignard; Pierre-Yves Dietrich; V Morand; A Lim; C Pannetier; Anne-Marie Leridant; T Hercend; Jos Even; Philippe Kourilsky; Frédéric Triebel
Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck.
Cancer research 1994;54(5):1292-7.
1994: C Genevée; V Chung; A Diu; T Hercend; Frédéric Triebel
TCR gene segments from at least one third of V alpha subfamilies rearrange at the delta locus.
Molecular immunology 1994;31(2):109-15.
1994: Bernard Escudier; Françoise Farace; Eric Angevin; F Charpentier; Gérard Nitenberg; Frédéric Triebel; T Hercend
Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1078-83.
1994: B Huard; P Gaulard; Florence Faure; T Hercend; Frédéric Triebel
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Immunogenetics 1994;39(3):213-7.
1993: H Michalaki; S Roman-Roman; Jean-François Nicolas; A Mackensen; J Thivolet; Frédéric Triebel; T Hercend; L Ferradini
In-situ preferential usage of V alpha 8 T-cell receptor gene segments in a patient with bullous pemphigoid.
Journal of autoimmunity 1993;6(6):827-39.
1993: L Ferradini; S Roman-Roman; O Azogui; C Genevée; S Viel; T Hercend; Frédéric Triebel
The use of anchored polymerase chain reaction for the study of large numbers of human T-cell receptor transcripts.
Molecular immunology 1993;30(13):1143-50.
1993: A Mackensen; L Ferradini; G Carcelain; Frédéric Triebel; Florence Faure; S Viel; T Hercend
Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma.
Cancer research 1993;53(15):3569-73.
1993: Françoise Farace; Eric Angevin; Bernard Escudier; Anne Caignard; Pierre-Yves Dietrich; C Genevee; T Hercend; Frédéric Triebel
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma.
International journal of cancer. Journal international du cancer 1993;54(5):741-7.
1993: Pierre-Yves Dietrich; Françoise Farace; Anne Caignard; Bernard Escudier; Frédéric Triebel
[Cancer immunotherapy: immunologic bases, reality and hopes].
Bulletin du cancer 1993;80(7):584-600.
1993: Eric Angevin; Françoise Farace; C Genevée; Michel Henry-Amar; Anne Caignard; Pierre-Yves Dietrich; Bernard Escudier; T Hercend; Frédéric Triebel
Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients.
International journal of cancer. Journal international du cancer 1993;54(1):60-7.
1993: S Roman-Roman; L Ferradini; O Azogui; Florence Faure; T Hercend; Frédéric Triebel
Alternatively spliced T cell receptor transcripts expressed in human T lymphocytes.
Molecular immunology 1993;30(5):423-31.
1993: Bernard Escudier; Françoise Farace; Eric Angevin; Frédéric Triebel; Sami Antoun; B Leclercq; M Brandely; A Aboudaram; Gérard Nitenberg; T Hercend
Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 1993;29A(5):724-8.
1992: Pierre-Yves Dietrich; Anne Caignard; A Diu; C Genevee; José-Luis Pico; Michel Henry-Amar; Jacques Bosq; Eric Angevin; Frédéric Triebel; T Hercend
Analysis of T-cell receptor variability in transplanted patients with acute graft-versus-host disease.
Blood 1992;80(9):2419-24.
1992: L Ferradini; S Roman-Roman; J Azocar; Marie-Françoise Avril; S Viel; Frédéric Triebel; T Hercend
Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis.
Cancer research 1992;52(17):4649-54.
1992: E Baixeras; B Huard; Christine Miossec; S Jitsukawa; Malcolm Martin; T Hercend; C Auffray; Frédéric Triebel; D Piatier-Tonneau
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
The Journal of experimental medicine 1992;176(2):327-37.
1992: C Genevée; A Diu; J Nierat; Anne Caignard; Pierre-Yves Dietrich; L Ferradini; S Roman-Roman; Frédéric Triebel; T Hercend
An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction.
European journal of immunology 1992;22(5):1261-9.
1991: Frédéric Triebel; T Hercend
[Human lymphocytes carrying the T gamma/delta receptor].
Presse médicale (Paris, France : 1983) 1991;20(43):2203-7.
1991: L Ferradini; S Roman-Roman; J Azocar; H Michalaki; Frédéric Triebel; T Hercend
Studies on the human T cell receptor alpha/beta variable region genes. II. Identification of four additional V beta subfamilies.
European journal of immunology 1991;21(4):935-42.
1991: S Roman-Roman; L Ferradini; J Azocar; C Genevée; T Hercend; Frédéric Triebel
Studies on the human T cell receptor alpha/beta variable region genes. I. Identification of 7 additional V alpha subfamilies and 14 J alpha gene segments.
European journal of immunology 1991;21(4):927-33.
1991: Christine Miossec; Anne Caignard; L Ferradini; S Roman-Roman; Florence Faure; H Michalaki; Frédéric Triebel; T Hercend
Molecular characterization of human T cell receptor alpha chains including a V delta 1-encoded variable segment.
European journal of immunology 1991;21(4):1061-4.
1990: T Hercend; Françoise Farace; D Baume; F Charpentier; J P Droz; Frédéric Triebel; Bernard Escudier
Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Journal of biological response modifiers 1990;9(6):546-55.
1990: E Baixeras; S Roman-Roman; S Jitsukawa; C Genevee; S Mechiche; E Viegas-Pequignot; T Hercend; Frédéric Triebel
Cloning and expression of a lymphocyte activation gene (LAG-1).
Molecular immunology 1990;27(11):1091-102.
1990: Françoise Farace; C Mathiot; M Brandely; Thomas Tursz; T Dorval; P Pouillart; Frédéric Triebel; T Hercend; W H Fridman
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Clinical and experimental immunology 1990;82(2):194-9.
1990: Fathia Mami-Chouaib; Christine Miossec; P Del Porto; Caroline Flament; Frédéric Triebel; T Hercend
T cell target 1 (TCT.1): a novel target molecule for human non-major histocompatibility complex-restricted T lymphocytes.
The Journal of experimental medicine 1990;172(4):1071-82.
1990: Frédéric Triebel
Gamma/delta T cells: from controlled development to functional programs.
Research in immunology 1990;141(7):626-30.
1990: P Lang; I Vitté-Mony; Françoise Farace; Rodica Stancou; Frédéric Triebel; Bernard Escudier; T Hercend; Jacques Bertoglio
In vivo activation of LAK cells during systemic IL-2 therapy.
European cytokine network 1990;1(3):185-8.
1990: Florence Faure; Christine Miossec; S Jitsukawa; Frédéric Triebel; T Hercend
The gamma/delta T cell receptor expressed on human peripheral blood lymphocytes.
European cytokine network 1990;1(2):65-9.
1990: Frédéric Triebel; S Jitsukawa; E Baixeras; S Roman-Roman; C Genevee; E Viegas-Pequignot; T Hercend
LAG-3, a novel lymphocyte activation gene closely related to CD4.
The Journal of experimental medicine 1990;171(5):1393-405.
1990: Christine Miossec; Florence Faure; L Ferradini; S Roman-Roman; S Jitsukawa; S Ferrini; A Moretta; Frédéric Triebel; T Hercend
Further analysis of the T cell receptor gamma/delta+ peripheral lymphocyte subset. The V delta 1 gene segment is expressed with either C alpha or C delta.
The Journal of experimental medicine 1990;171(4):1171-88.
1990: Frédéric Triebel
Use of monoclonal antibodies specific for distinct variable or constant regions of the gamma/delta T cell receptor in normal and pathological conditions.
Disease markers 1990;8(2):47-54.
1989: S Roman-Roman; E Baixeras; C Genevée; T Hercend; Frédéric Triebel
The T-cell receptor V delta genes predominantly used by human peripheral gamma/delta+ T lymphocytes are not rearranged in CD3- natural killer cells.
Human immunology 1989;26(2):75-83.
1989: Fathia Mami-Chouaib; S Jitsukawa; Florence Faure; B Vasina; C Genevee; T Hercend; Frédéric Triebel
cDNA cloning of functional T cell receptor gamma/delta chains expressed in human peripheral blood lymphocytes.
European journal of immunology 1989;19(9):1545-9.
1988: Frédéric Triebel; Florence Faure; Fathia Mami-Chouaib; S Jitsukawa; A Griscelli; C Genevée; S Roman-Roman; T Hercend
A novel human V delta gene expressed predominantly in the Ti gamma A fraction of gamma/delta+ peripheral lymphocytes.
European journal of immunology 1988;18(12):2021-7.
1988: Florence Faure; S Jitsukawa; Frédéric Triebel; T Hercend
Characterization of human peripheral lymphocytes expressing the CD3-gamma/delta complex with anti-receptor monoclonal antibodies.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(10):3357-60.
1988: S Jitsukawa; Frédéric Triebel; Florence Faure; Christine Miossec; T Hercend
Cloned CD3+ TcR alpha/beta- Ti gamma A- peripheral blood lymphocytes compared to the Ti gamma A+ counterparts: structural differences of the gamma/delta receptor and functional heterogeneity.
European journal of immunology 1988;18(11):1671-9.
1988: Florence Faure; S Jitsukawa; S Meuer; C Bohuon; Frédéric Triebel; T Hercend
Identification of a CD2- CD3+ T cell receptor-gamma+ peripheral blood lymphocyte subpopulation.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(7):2128-32.
1988: Florence Faure; S Jitsukawa; Frédéric Triebel; T Hercend
CD3/Ti gamma A: a functional gamma-receptor complex expressed on human peripheral lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(5):1372-9.
1988: Frédéric Triebel; Florence Faure; M Graziani; S Jitsukawa; Marie-Paule Lefranc; T Hercend
A unique V-J-C-rearranged gene encodes a gamma protein expressed on the majority of CD3+ T cell receptor-alpha/beta- circulating lymphocytes.
The Journal of experimental medicine 1988;167(2):694-9.
1988: T Hercend; Frédéric Triebel
[Principles of treatment with cells called "LAK" cells].
Bulletin du cancer 1988;75(9):879-84.
1988: Frédéric Triebel; R Breathnach; M Graziani; T Hercend; P Debre
Evidence for expression of two distinct T cell receptor beta-chain transcripts in a human diphtheria toxoid-specific T cell clone.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(1):300-4.
1987: S Jitsukawa; Florence Faure; M Lipinski; Frédéric Triebel; T Hercend
A novel subset of human lymphocytes with a T cell receptor-gamma complex.
The Journal of experimental medicine 1987;166(4):1192-7.
1987: Frédéric Triebel; M Graziani; Florence Faure; S Jitsukawa; T Hercend
Cloned human CD3- lymphocytes with natural killer-like activity do not express nor rearrange T cell receptor gamma genes.
European journal of immunology 1987;17(8):1209-12.
1987: P Moingeon; S Jitsukawa; Florence Faure; F Troalen; Frédéric Triebel; M Graziani; F Forestier; D Bellet; C Bohuon; T Hercend
A gamma-chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity.
Nature 1987;325(6106):723-6.